Business
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn's and Colitis Organization Congress (ECCO 2025).
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Safety profile remains consistent with previous studies, with no new safety findings were observed","length":98,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":358,"olType":false},{"type":"text","content":"SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn's and Colitis Organization Congress (ECCO 2025).","length":477,"tagName":"p"},{"type":"text","content":"Etrasimod, a next-generation, once-daily selective sphingosine-1-phosphate (S1P) receptor modulator, is being developed for the treatment of moderately to severely active ulcerative colitis (UC). To date, etrasimod is the only advanced UC therapy that has completed a large-scale, randomized, controlled pivotal study in the Asia-Pacific region. The findings of the ES101002 study provide robust evidence supporting the use of etrasimod in UC patients.","length":452,"tagName":"p"},{"type":"text","content":"The positive results come from a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of etrasimod conducted in the Asian region. This is the largest pivotal Phase 3 study to date in Asian population with moderately to severely active ulcerative colitis. A total of 340 eligible patients with an inadequate response to, loss of response to, or intolerance to at least 1 prior UC treatment were randomized in a 2:1 ratio to receive either etrasimod 2mg once daily or placebo for 12 weeks in the induction period. All patients who completed the induction treatment and were responders at week 12 entered a 40-week maintenance period in which patients were re-randomize...